Tapering belimumab in patients with systemic lupus erythematosus: a single-centre experience

Rheumatology (Oxford). 2023 Feb 1;62(2):e18-e20. doi: 10.1093/rheumatology/keac456.

Authors

Micaela Fredi¹, Tamara Vojinovic¹, Francesca Regola¹, Giorgia Babaglioni², Daria Bettoni², Laura Andreoli¹, Angela Tincani¹, Franco Franceschini¹

Affiliations

¹ Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia.
² Farmacia Aziendale, ASST Spedali Civili Brescia, Brescia, Italy.

PMID: 35946521
DOI: 10.1093/rheumatology/keac456

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Humans
Immunosuppressive Agents / therapeutic use
Lupus Erythematosus, Systemic* / drug therapy
Treatment Outcome

Substances

belimumab
Antibodies, Monoclonal, Humanized
Immunosuppressive Agents